Eric Honroth

Eric Honroth is the President and Chief Executive Officer of AngioDynamics, a medical technology company listed on Nasdaq under the ticker ANGO. He is known for his leadership of the Life Science business at Getinge, the Swedish medical technology group, before he moved to AngioDynamics in November 2026.

Career timeline

• 2026 to present: President and Chief Executive Officer, and member of the Board of Directors, AngioDynamics
• 2022 to 2026: President, Life Science, and member of the Executive Team, Getinge
• 2018 to 2022: President, North America Region, Getinge
• Earlier: Senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific

Path to CEO

Eric Honroth has worked in medical devices and life sciences for more than 20 years. Before he joined Getinge, he held senior leadership roles at several large medical technology companies. AngioDynamics names Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific among them. The public sources do not give the titles or the years of these roles.

He joined Getinge in 2018 as President of its North America Region. AngioDynamics describes that business as a 1.2 billion dollar operation. On 1 April 2022 Getinge made him President of its Life Science business area and a member of the group Executive Team. He held that role for more than four years.

On 7 October 2026 Getinge announced that he would leave the company for an opportunity outside the group, with his last day on 31 October 2026. One day later, on 8 October 2026, AngioDynamics announced that its board had appointed him President and Chief Executive Officer and a director, effective 2 November 2026. He succeeded Jim Clemmer, who had led AngioDynamics for ten years and who agreed to stay on as a consultant during the handover. Outside his company roles, he serves on the Marketing Advisory Board of the Farmer School of Business at Miami University.

Quick facts

What is Eric Honroth known for?

He is the CEO of AngioDynamics since November 2026. Before that he ran the Life Science business and, earlier, the North American business of Getinge.

Where did Eric Honroth study?

He holds a bachelor's degree in marketing from Miami University in Ohio, according to the university's advisory-board profile.

Who did Eric Honroth succeed at AngioDynamics?

He succeeded Jim Clemmer, who had been CEO for ten years. Jim Clemmer left the board on 2 November 2026 and agreed to act as a consultant during the transition.

What did Eric Honroth do at Getinge?

He joined Getinge in 2018 to lead its North America Region. From April 2022 to October 2026 he was President of the Life Science business area and sat on the group Executive Team.

When did Eric Honroth become CEO of AngioDynamics?

His appointment was announced on 8 October 2026 and took effect on 2 November 2026.

Related profiles

• Jennifer L. Davis, CEO-elect, Align Technology
• David Ricks, Chair and CEO, Eli Lilly
• Gail Boudreaux, President and CEO, Elevance Health
• Karen Lynch, former President and CEO, CVS Health

Sources

• AngioDynamics (SEC Form 8-K, Exhibit 99.1): AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
• Endovascular Today: AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer
• HMP Global, Vascular Disease Management: AngioDynamics announces appointment of Eric Honroth
• BioSpace (Getinge release): Getinge appoints Eric Honroth as President Life Science
• Getinge via Placera: Getinge announces departure of Eric Honroth, President Life Science
• Miami University, Farmer School of Business: Eric Honroth

Last updated: 2026-11-13

About this page

This is an unofficial profile. Whoo compiled it from the public sources listed above. Eric Honroth did not write or approve it. To correct or remove this page, write to [email protected].

Create your own page from your résumé